{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T23:34:33Z","timestamp":1778283273889,"version":"3.51.4"},"reference-count":32,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec>\n<jats:title>Purpose<\/jats:title>\n<jats:p>This study seeks to reassess and enhance the dosing strategies of letermovir and maribavir for treating cytomegalovirus (CMV) infection, aiming to propose adjustments that could improve therapeutic effectiveness.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Pre-existing population pharmacokinetic models were used alongside Monte Carlo simulations to evaluate the dosing strategies of letermovir and maribavir in CMV treatment. The simulations assessed the probability of target attainment for current and alternative dosing regimens, including scenarios with missed doses.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>For letermovir, a loading dose on the first day of treatment initiation appeared more effective than the current strategy without a loading dose. Additionally, in cases of missed doses, doubling the dose upon resumption was more effective than returning to the normal dosage. For maribavir, the current 400mg BID regimen only covers the lower end of the inhibitory concentration 50 range, suggesting a potential benefit from increasing the doses. Simulations indicated that for missed doses, all tested regimens only covered the lower range of inhibitory concentrations, but the current strategy of resuming the normal dosage provided the lowest chances of target attainment.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Our findings suggest a strong rationale to reconsider and potentially modify the approved dosing guidelines for letermovir and maribavir in CMV treatment. Adjusting dosing regimens, including the use of loading doses and increased doses after missed doses, could enhance treatment outcomes by ensuring higher probabilities of achieving therapeutic targets and better managing missed doses.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0321180","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T17:29:04Z","timestamp":1745861344000},"page":"e0321180","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["Optimizing CMV therapy: Population pharmacokinetics and Monte Carlo simulations for letermovir and maribavir dosage"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-3356-557X","authenticated-orcid":true,"given":"Yeleen","family":"Fromage","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamza","family":"Sayadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9787-1421","authenticated-orcid":true,"given":"Sophie","family":"Alain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Marquet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Peytavin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1695-0695","authenticated-orcid":true,"given":"Jean-Baptiste","family":"Woillard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"issue":"12","key":"pone.0321180.ref001","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1093\/jac\/dkq368","article-title":"Drug-resistant cytomegalovirus in transplant recipients: a French cohort study","volume":"65","author":"S Hantz","year":"2010","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 4","key":"pone.0321180.ref002","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/ajt.12103","article-title":"AST infectious diseases community of practice. cytomegalovirus in solid organ transplantation","volume":"13","author":"RR Razonable","year":"mars 2013","journal-title":"Am J Transplant"},{"issue":"23","key":"pone.0321180.ref003","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1182\/blood-2016-06-688432","article-title":"How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients","volume":"128","author":"F El Chaer","year":"2016","journal-title":"Blood"},{"issue":"12","key":"pone.0321180.ref004","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1080\/14656566.2019.1637418","article-title":"An overview of letermovir: a cytomegalovirus prophylactic option","volume":"20","author":"G Gerna","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"pone.0321180.ref005"},{"issue":"4","key":"pone.0321180.ref006","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/rmv.615","article-title":"Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir","volume":"19","author":"MN Prichard","year":"2009","journal-title":"Rev Med Virol"},{"key":"pone.0321180.ref007"},{"issue":"4","key":"pone.0321180.ref008","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1128\/AAC.47.4.1334-1342.2003","article-title":"Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects","volume":"47","author":"LH Wang","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"issue":"25","key":"pone.0321180.ref009","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"FM Marty","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"pone.0321180.ref010","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1093\/cid\/ciab988","article-title":"Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: Results from a phase 3 randomized clinical trial","volume":"75","author":"RK Avery","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"2\u20133","key":"pone.0321180.ref011","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.antiviral.2006.05.002","article-title":"Antiviral drugs for cytomegalovirus diseases","volume":"71","author":"KK Biron","year":"2006","journal-title":"Antiviral Res"},{"key":"pone.0321180.ref012"},{"issue":"4","key":"pone.0321180.ref013","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1038\/psp.2013.14","article-title":"Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods","volume":"2","author":"DR Mould","year":"2013","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"2","key":"pone.0321180.ref014","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/jcph.1633","article-title":"Parametric approaches in population pharmacokinetics","volume":"62","author":"M Guidi","year":"2022","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"pone.0321180.ref015","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/psp4.12593","article-title":"Population pharmacokinetics of letermovir following oral and intravenous administration in healthy participants and allogeneic hematopoietic cell transplantation recipients","volume":"10","author":"M Prohn","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"6","key":"pone.0321180.ref016","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/cts.12483","article-title":"Intravenous hydroxypropyl \u03b2-cyclodextrin formulation of letermovir: a phase I, randomized, single-ascending, and multiple-dose trial","volume":"10","author":"K Erb-Zohar","year":"2017","journal-title":"Clin Transl Sci"},{"issue":"19","key":"pone.0321180.ref017","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1309533","article-title":"Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation","volume":"370","author":"RF Chemaly","year":"2014","journal-title":"N Engl J Med"},{"issue":"8","key":"pone.0321180.ref018","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/psp4.12810","article-title":"Machine learning algorithms to estimate everolimus exposure trained on simulated and patient pharmacokinetic profiles","volume":"11","author":"M Labriffe","year":"2022","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"5","key":"pone.0321180.ref019","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/psp4.12943","article-title":"Population pharmacokinetic modeling and simulation of maribavir to support dose selection and regulatory approval in adolescents with posttransplant refractory cytomegalovirus","volume":"12","author":"K Sun","year":"2023","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"8","key":"pone.0321180.ref020","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1093\/cid\/ciy706","article-title":"Maribavir for refractory or resistant cytomegalovirus infections in hematopoietic-cell or solid-organ transplant recipients: a randomized, dose-ranging, double-blind, phase 2 study","volume":"68","author":"GA Papanicolaou","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"12","key":"pone.0321180.ref021","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/psp4.12467","article-title":"Quantitative systems pharmacology and physiologically-based pharmacokinetic modeling with mrgsolve: a hands-on tutorial","volume":"8","author":"A Elmokadem","year":"2019","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"3","key":"pone.0321180.ref022","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/FTD.0000000000001169","article-title":"In silico pharmacokinetics evaluation of forgiveness for doravirine and rilpivirine","volume":"46","author":"Y Fromage","year":"2024","journal-title":"Ther Drug Monit"},{"issue":"6","key":"pone.0321180.ref023","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/cts.13509","article-title":"Developing a mechanistic understanding of the nonlinear pharmacokinetics of letermovir and prospective drug interaction with everolimus using physiological-based pharmacokinetic modeling","volume":"16","author":"K Menzel","year":"2023","journal-title":"Clin Transl Sci"},{"key":"pone.0321180.ref024","article-title":"Physiologically based pharmacokinetic modeling for maribavir to inform dosing in drug-drug interaction scenarios with CYP3A4 inducers and inhibitors","author":"G Chen","year":"2023","journal-title":"J Clin Pharmacol"},{"issue":"8","key":"pone.0321180.ref025","doi-asserted-by":"crossref","first-page":"e0065722","DOI":"10.1128\/aac.00657-22","article-title":"Therapeutic drug monitoring of orally administered letermovir prophylaxis in allogeneic hematopoietic stem cell transplant recipients","volume":"66","author":"L Royston","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"pone.0321180.ref026","first-page":"2253","article-title":"Letermovir breakthroughs during the French named patient programme: Interest of monitoring blood concentration in clinical practice","volume":"75","author":"S Alain","year":"2020","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"pone.0321180.ref027","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/infdis\/jiad293","article-title":"Drug resistance assessed in a phase 3 clinical trial of maribavir therapy for refractory or resistant cytomegalovirus infection in transplant recipients","volume":"229","author":"S Chou","year":"2024","journal-title":"J Infect Dis"},{"issue":"2","key":"pone.0321180.ref028","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1016\/S2352-3018(21)00300-3","article-title":"A 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 (ANRS 170 QUATUOR): A randomised, open-label, multicentre, parallel, non-inferiority trial","volume":"9","author":"R Landman","year":"2022","journal-title":"Lancet HIV"},{"issue":"9","key":"pone.0321180.ref029","doi-asserted-by":"crossref","first-page":"e421","DOI":"10.1016\/S2352-3018(16)30054-6","article-title":"Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents, and young adults (BREATHER): A randomised, open-label, non-inferiority, phase 2\/3 trial","volume":"3","author":"BREATHER (PENTA 16) Trial Group.","year":"2016","journal-title":"Lancet HIV"},{"issue":"3","key":"pone.0321180.ref030","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1093\/jac\/dkx434","article-title":"Four-days-a-week antiretroviral maintenance therapy in virologically controlled HIV-1-infected adults: The ANRS 162-4D trial","volume":"73","author":"P de Truchis","year":"2018","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"pone.0321180.ref031","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMoa1714656","article-title":"Maribavir for preemptive treatment of cytomegalovirus reactivation","volume":"381","author":"J Maertens","year":"2019","journal-title":"N Engl J Med"},{"issue":"9","key":"pone.0321180.ref032","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1128\/AAC.46.9.2969-2976.2002","article-title":"Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding","volume":"46","author":"JP Lalezari","year":"2002","journal-title":"Antimicrob Agents Chemother"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0321180","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T17:29:13Z","timestamp":1745861353000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0321180"}},"subtitle":[],"editor":[{"given":"Hideo","family":"Kato","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":32,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4,28]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0321180","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,28]]}}}